However, controversial results have also been published in groups of GBM patients, in which MGMT-status is not associated with differences in outcome: Costa et al. reports on 90 GBM-patients treated with temozolomide-based chemoradiation where MGMT promoter methylation was not associated with increased outcome [10]. Here, MGMT is linked to glioblastoma.